^
13h
ALMS1-IT1: A Key Player in the Novel Disulfidptosis-Related LncRNA Prognostic Signature for Head and Neck Squamous Cell Carcinoma. (PubMed, Biomolecules)
Knockdown of ALMS1-IT1 inhibited the PPP, contributing to a decline in NADPH levels, which resulted in the formation of multiple intermolecular disulfide bonds between actin cytoskeleton proteins and the collapse of F-actin in the cytoplasm. Therefore, ALMS1-IT1, which is highly expressed in SLC7A11high cells, can be considered a promising therapeutic target for disulfidptosis-focused treatment strategies for cancer and other diseases.
Journal
|
SLC7A11 (Solute Carrier Family 7 Member 11)
|
SLC7A11 expression
14h
SP1 Gene Methylation in Head and Neck Squamous Cell Cancer in HPV-Negative Patients. (PubMed, Genes (Basel))
The methylation of the SP1 gene in tumor DNA suppresses its expression, hinders HNSCC cell proliferation regulation, and could be a molecular indicator of malignant cell growth. The study of DNA methylation of various genes involved in carcinogenesis is promising because hypermethylated promoters can serve as potential biomarkers of disease.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SMAD3 (SMAD Family Member 3) • SP1 (Sp1 Transcription Factor)
14h
Gene-Expression Patterns of Tumor and Peritumor Tissues of Smoking and Non-Smoking HPV-Negative Patients with Head and Neck Squamous Cell Carcinoma. (PubMed, Biomedicines)
The largest group included 10 genes: TIMP1, TIMP2, WEE1, YAP, HIF1A, PI3KCA, UTP14A, APIP, PTEN, and SLC26A6. The genetic signatures associated with smoking habits that we have found may serve as a prerequisite for the development of diagnostic panels/tests predicting responses to different therapeutic strategies for HNSCC.
Journal
|
EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • IL6 (Interleukin 6) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • KRT17 (Keratin 17) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • TP63 (Tumor protein 63)
|
EGFR expression • CD44 expression • HIF1A expression • IL6 expression
14h
Revisiting Multi-Omics Data to Unravel Galectins as Prognostic Factors in Head and Neck Squamous Cell Carcinoma. (PubMed, Biomedicines)
Gal-1 and Gal-3BP are the most promising galectins in HNSCC. Furthermore, this study highlights the need for further studies to evaluate galectins in HNSCC and clarify the role of individual Gals in the patient's stratification.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 expression
14h
Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy. (PubMed, Biomedicines)
The combinatorial efficacy of volasertib and radiotherapy was replicated in xenograft mouse models. These findings highlight the potential of adding PLK-1 inhibitors to adjuvant therapy regimens in OSCC.
Journal
|
PLK1 (Polo Like Kinase 1)
|
volasertib (NBL-001)
15h
Synthetic Circular RNA for microRNA-1269a Suppresses Tumor Progression in Oral Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
In particular, phospholipase C gamma 2 (PLCG2), which is related to OSCC clinical stage and overall survival, was affected by the circRNA-1269a/miR-1269a axis. Taken together, synthetic circRNA-1269a inhibits tumor progression via miR-1269a and its downstream targets, indicating that artificial circRNAs could represent an effective OSCC therapeutic.
Journal • Circular RNA
|
PLCG2 (Phospholipase C Gamma 2) • MIR1269A (MicroRNA 1269a)
15h
PIP4K2B Protein Regulation by NSD1 in HPV-Negative Head and Neck Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
In conclusion, our findings implicate PIP4K2B as a novel NSD1-dependent protein in HNSCC, suggesting its potential significance for laryngeal cancer cell survival. This insight contributes to our understanding of the molecular landscape in HNSCC and establishes PIP4KB as a promising target for drug development.
Journal
|
NSD1 (Nuclear Receptor Binding SET Domain Protein 1)
15h
EMT Dynamics in Lymph Node Metastasis of Oral Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
Our findings demonstrate that EMT marker expression correlates with lymph node metastasis in OSCC. Developing therapies targeting regulators such as N-cadherin may prevent metastasis and improve outcomes.
Journal
|
CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
15h
Analysis of the effect of CCR7 on the microenvironment of mouse oral squamous cell carcinoma by single-cell RNA sequencing technology. (PubMed, J Exp Clin Cancer Res)
CCR7 gene knockout can significantly inhibit the growth of mouse oral squamous cell carcinoma by promoting the polarization of M2 macrophages.
Preclinical • Journal
|
CCR7 (Chemokine (C-C motif) receptor 7) • DUSP1 (Dual Specificity Phosphatase 1)
21h
Enrollment open • Metastases
|
LGALS3 (Galectin 3)
|
Keytruda (pembrolizumab) • GB1211
21h
ADJORL1: Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=140, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Feb 2024 --> May 2026 | Trial primary completion date: Aug 2021 --> May 2026
Trial completion date • Trial primary completion date • Surgery
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
23h
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease (clinicaltrials.gov)
P1, N=16, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Mar 2024 | Trial primary completion date: Apr 2025 --> Mar 2024
Trial completion • Trial completion date • Trial primary completion date • Metastases
23h
ABBIMUNE: A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (clinicaltrials.gov)
P1/2, N=54, Active, not recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Trial primary completion date: Jun 2023 --> Jun 2024
Trial primary completion date • Combination therapy • Metastases
|
Imfinzi (durvalumab) • Imjudo (tremelimumab)
24h
KEYNOTE-877: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab (clinicaltrials.gov)
P1/2, N=323, Active, not recruiting, RAPT Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Sep 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • tivumecirnon (FLX475)
1d
Chemerin promotes invasion of oral squamous cell carcinoma by stimulating IL-6 and TNF-α production via STAT3 activation. (PubMed, Mol Biol Rep)
Our findings indicate that chemerin may play a role in advancing OSCC progression by increasing production of IL-6 and TNF-α, perhaps via a mechanism involving STAT3 signaling.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15)
1d
Inhibition of Oral Tumorigenesis by Antitumor B (clinicaltrials.gov)
P1, N=14, Recruiting, Medical College of Wisconsin | N=28 --> 14 | Trial primary completion date: May 2025 --> Sep 2024
Enrollment change • Trial primary completion date
1d
Single cell deciphering of progression trajectories of the tumor ecosystem in head and neck cancer. (PubMed, Nat Commun)
Finally, we delineate the distinct features of malignant epithelial cells in primary and recurrent tumors, providing a theoretical foundation for the precise selection of targeted therapy for tumors at different stages. In summary, the current study offers a comprehensive landscape and deep insight into epithelial and microenvironmental reprogramming throughout initiation, progression, lymph node metastasis and recurrence of head and neck squamous cell carcinoma.
Journal
|
CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • POSTN (Periostin)
|
CXCL13 expression • CXCL13 overexpression
1d
Different Influence Pattern of Conventional and Alternative Sources of Smoking on Adhesion Molecules and Cytokine Secretion in THP-1 Monocytes. (PubMed, Anticancer Res)
Our data indicate differential immunological consequences of different conventional and alternative smoking sources with and without nicotine. Further comprehensive analysis as well as in vivo investigations on peripheral blood monocyte subsets from smoking individuals using different smoking sources are required to better understand the impact on monocyte characteristics, especially with regard to the development of cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
1d
Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo. (PubMed, Mol Biol Rep)
In HPV-negative HNSCC, CDK4/6 inhibitor shows promising anti-tumor effects, which exhibits a synergistic effect when combined with EGFR inhibitor only in specific drug concentration and mouse model.
Preclinical • Journal
|
CCND1 (Cyclin D1) • MMP9 (Matrix metallopeptidase 9)
|
CCND1 overexpression
|
Erbitux (cetuximab) • cisplatin • Ibrance (palbociclib)
1d
Expression Profile of Circulating Exosomal microRNAs in Leukoplakia, Oral Submucous Fibrosis, and Combined Lesions of Leukoplakia and Oral Submucous Fibrosis. (PubMed, Head Neck Pathol)
Plasma circulating exosomal miRNAs miRNA 21, miRNA 145, and miRNA 184 expression could be a novel panel of plasma biomarkers to categorise case group (leukoplakia, OSMF, leukoplakia and OSMF) patients with a high risk of malignant transformation.
Journal
|
MIR21 (MicroRNA 21)
1d
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro. (PubMed, Cancer Chemother Pharmacol)
BI 2536 enhanced the sensitivity of HNSCC cells to erastin, which provides a new perspective for cancer treatment.
Preclinical • Journal
|
PLK1 (Polo Like Kinase 1)
|
erastin • BI2536
1d
Integrative methylome and transcriptome analysis reveals epigenetic regulation of Fusobacterium nucleatum in laryngeal cancer. (PubMed, Microb Genom)
This analysis provides a novel understanding of the impact of F. nucleatum in the methylome and transcriptome of laryngeal cancer. Identification of these epigenetic regulatory mechanisms opens up new avenues for mechanistic studies to explore novel therapeutic strategies.
Journal
|
JAK3 (Janus Kinase 3)
1d
Serum Pro-Inflammatory Cytokines and Leptin as Potential Biomarkers for Treatment Response and Toxicity in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. (PubMed, Diseases)
The results showed that serum cytokines and leptin levels varied depending on the response to treatment, with patients who had a complete or partial response (PR) showing significant decreases in IL-1 β, IL-6, and TNF-α levels and significant increases in IL-2 and leptin levels after treatment, with an improvement in cachexia. These results imply that variations in serum pro-inflammatory cytokines and leptin levels are likely related to the therapeutic effectiveness in HNSCC and may act as biomarkers for treatment response.
Journal • Metastases
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL1B (Interleukin 1, beta) • LEP (Leptin)
1d
ITGAV Promotes the Progression of Head and Neck Squamous Cell Carcinoma. (PubMed, Curr Oncol)
In addition, chromatin immunoprecipitation (ChIP) assays indicated that SOX11 bound to the promoter of ITGAV gene, and SOX11 knockdown resulted in decreased ITGAV expression in HNSCC cells. In conclusion, our studies suggest that ITGAV promotes the progression of HNSCC cells and may be regulated by SOX11 in HNSCC cells.
Journal
|
SOX11 (SRY-Box Transcription Factor 11) • ITGAV (Integrin Subunit Alpha V)
1d
LRRC59 promotes the progression of oral squamous cell carcinoma by interacting with SRP pathway components and enhancing the secretion of CKAP4-containing exosomes. (PubMed, Heliyon)
We also revealed that the LRRC59-CKAP4 axis was a crucial regulator of CKAP4-containing exosome secretion in OSCC cells for migration and invasion. Therefore, based on our findings, LRRC59 may serve as a potential biomarker for OSCC patients, and LRRC59-induced exosome secretion via the CKAP4 axis may serve as a potential therapeutic target for OSCC.
Journal
|
CKAP4 (Cytoskeleton Associated Protein 4)
1d
RGIE: A Gene Selection Method Related to Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma. (PubMed, Curr Radiopharm)
RGIE is effective in screening genes related to HNSCC-RR. This approach may help guide clinical treatment modalities for patients and develop potential treatments.
Journal
|
TCF7L2 (Transcription Factor 7 Like 2) • SPAG1 (Sperm Associated Antigen 1)
2d
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Apr 2024 --> Dec 2024
Trial completion date
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
2d
PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
P1, N=166, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2024 --> Oct 2024
Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Leclaza (lazertinib) • amivantamab SC (Ami-LC)
2d
New P1 trial • Metastases
2d
3D Specimen Maps for RT Planning (clinicaltrials.gov)
P=N/A, N=13, Recruiting, Vanderbilt University Medical Center | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
Trial completion date • Trial primary completion date
2d
Enrollment closed • Combination therapy • Metastases
|
SIRPA (Signal Regulatory Protein Alpha)
|
Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
2d
Development and experimental verification of a prognosis model for disulfidptosis-associated genes in HNSCC. (PubMed, Medicine (Baltimore))
Overall, we present a comprehensive overview of the DAG profile in HNSCC and develop a new risk model for the therapeutic status and prognosis of patients with HNSCC. Our findings highlight the potential clinical significance of DAG and suggest that disulfidptosis may be a potential therapeutic target for patients with HNSCC.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
2d
Inhibin A contributes to the tumorigenesis of oral squamous cell carcinoma by KIAA1429-mediated m6A modification. (PubMed, J Oral Pathol Med)
Inhibin A promotes the tumorigenesis of oral squamous cell carcinoma by KIAA1429-mediated N6-methyladenosine modification. This study adds to our current knowledge of the molecular mechanisms underlying oral squamous cell carcinoma malignancy.
Journal
|
VIRMA (Vir Like M6A Methyltransferase Associated)
2d
Involvement of TGFBI-TAGLN axis in cancer stem cell property of head and neck squamous cell carcinoma. (PubMed, Sci Rep)
In conclusion, our findings suggest that TGFBI may promote CSC properties through the upregulation of TAGLN. These novel insights shed light on the involvement of the TGFBI-TAGLN axis in HNSCC progression and hold implications for the development of targeted therapies.
Journal • Cancer stem
|
TAGLN (Transgelin) • TGFBI (Transforming Growth Factor Beta Induced)
|
TAGLN expression
2d
Ginsenoside Rb1 Deters Cell Proliferation, Induces Apoptosis, Alleviates Oxidative Stress, and Antimetastasis in Oral Squamous Carcinoma Cells. (PubMed, Appl Biochem Biotechnol)
OSCC administration significantly reduced the levels of SOD, GSH, GPx, and CAT, increasing the levels of PCI-9A and PCI-13 cells, while GRb1 improved this situation. Therefore, we propose that Ginsenoside Rb1 could be an alternative therapeutic strategy for OSCC therapy.
Journal
|
PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • ANXA5 (Annexin A5)
3d
Expression of Aberrant MicroRNAs and p16INK4a Associated with HPV (6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 52, 53, and 56) in Oral Dysplasia and Squamous Cell Carcinoma: A Retrospective Study. (PubMed, Turk Patoloji Derg)
MiRNA-21, miRNA-22, and miRNA-224, besides p16 INK4a, could be used as indicators for HPV-associated OD and OSCC as their expression is attributed to the HPV oncoprotein. Further studies using follow-up data should be done to correlate it with miRNA overexpression.
Retrospective data • Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MIR21 (MicroRNA 21)
3d
Separating distant recurrences from second primaries in head and neck squamous cell carcinomas - A DAHANCA group analysis on paired tumor samples. (PubMed, Head Neck)
One-third of patients with DMs in HNSCC lack a genetic relationship with the primary tumors. The risk of misclassification is most prominent for patients with lung involvement.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation
3d
LncRNA RASAL2-AS1 promotes METTL14-mediated m6A methylation in the proliferation and progression of head and neck squamous cell carcinoma. (PubMed, Cancer Cell Int)
Our study highlights the functional importance of the LncRNA RASAL2-AS1 in HNSCC and might assist in the development of a prognostic stratification and therapeutic approach. Which regulates HNSCC with the dependence of m6a manner.
Journal
|
METTL14 (Methyltransferase 14)
3d
The upregulation of VGF enhances the progression of oral squamous carcinoma. (PubMed, Cancer Cell Int)
This study highlights the multifaceted role of VGF in OSCC pathogenesis and introduces the miR-432-5p-VGF-IL23R regulatory axis as a critical mediator. The combined expression of VGF and IL23R emerges as a potent predictor of survival in oral carcinoma cases, suggesting potential implications for future therapeutic strategies.
Journal
|
MIR432 (MicroRNA 432)
3d
Comparative response to PDT with methyl-aminolevulinate and temoporfin in cutaneous and oral squamous cell carcinoma cells. (PubMed, Sci Rep)
Therefore, we propose that intracellular localization of GSK3β could be a good marker of response to PDT in HNSCC. Although the molecular mechanism of response to PDT needs further elucidation, this work shows that the most MAL-resistant line of CSCC is more sensitive to Temoporfin.
Journal
|
GSK3B (Glycogen Synthase Kinase 3 Beta)
|
Foscan (temoporfin)
3d
Personal Health Train for Radiation Oncology in India and The Netherlands (clinicaltrials.gov)
P=N/A, N=2000, Active, not recruiting, Maastricht Radiation Oncology | Trial completion date: Feb 2024 --> Nov 2024 | Trial primary completion date: Dec 2023 --> May 2024
Trial completion date • Trial primary completion date
3d
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) (clinicaltrials.gov)
P2, N=43, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial primary completion date: Sep 2023 --> Sep 2024
Trial primary completion date • Combination therapy
|
carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel